ACE and type 2 diabetes mellitus: Antihypertensive therapy reduces the risk of albuminuria, and in individuals with T2DM and stabilized CKD (eGFR), angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy reduces the risk of progression to end-stage kidney disease [18-20].